Phase 1/2 Trial of IOV-3001 Plus Lifileucel in Advanced Melanoma

Iovance Biotherapeutics in Nashville is launching an open-label study evaluating a modified interleukin-2 fusion protein (IOV-3001) in combination with lifileucel for previously treated unresectable or metastatic melanoma, including uveal and BRAF V600–mutant subtypes. This trial aims to establish safety and dosing parameters, potentially enhancing the immune response in a challenging melanoma population.